Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Nilgun Ozturk

Internal Medicine Baltimore, MD Medical Doctor

NPI 1609148469 CMS profile 892379

821 N Eutaw Street, Suite 308, Baltimore, MD 21201

Open in the dashboard

General payments

$576

31 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Nilgun Ozturk of Baltimore, MD is reported in the CMS Open Payments database as having received $576 across 31 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $77 4
2019 General $499 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nilgun Ozturk
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Nilgun Ozturk were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Nilgun Ozturk Internal Medicine median Middle half National median
2019 $499 $159 $48–$570 $163
2020 $77 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Janssen Pharmaceuticals, Inc $273 12 payments
  2. AstraZeneca Pharmaceuticals LP $95 5 payments
  3. Novartis Pharmaceuticals Corporation $84 5 payments
  4. Sunovion Pharmaceuticals Inc. $57 5 payments
  5. Biogen, Inc. $23 1 payment
  6. Astellas Pharma US Inc $17 1 payment
  7. ACADIA Pharmaceuticals Inc $17 1 payment
  8. Merck Sharp & Dohme Corporation $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $576 31 payments
Products named General payments · program years 2019–2020
  1. INVOKANA $210 3 payments
  2. LOKELMA $95 5 payments
  3. XARELTO $86 10 payments
  4. ENTRESTO $84 5 payments
  5. LONHALA MAGNAIR $35 3 payments
  6. APTIOM $22 2 payments
  7. MYRBETRIQ $17 1 payment
  8. NUPLAZID $17 1 payment
  9. PNEUMOVAX 23 $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

2,733

Median for Nephrology: 954

Drug cost

$188,797

Median for Nephrology: $127,050

Branded share of claims

14.3%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 117 $59,725
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 12 $51,060
Sevelamer Carbonate Generic 51 $16,058
Quetiapine Fumarate Er Quetiapine Fumarate Brand 14 $5,611
Atorvastatin Calcium Generic 216 $4,112
Pregabalin Generic 83 $3,495
Amlodipine Besylate Generic 186 $2,955
Mirtazapine Generic 90 $2,697
Baclofen Generic 55 $2,482
Carvedilol Generic 84 $2,162

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$177,775

Medicare's payments for the services billed

Medicare patients

254

Average age 78

Services billed

2,375

183 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 64%
Chronic kidney disease 64%
Heart failure 56%
Ischemic heart disease 54%
Depression 50%
Alzheimer's or dementia 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

31 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record